Today: 27 June 2026
Microsoft Stock Today (MSFT): Near $485 as AI and Cloud Drive $3.6 Trillion Value

Microsoft Stock Today (MSFT): Near $485 as AI and Cloud Drive $3.6 Trillion Value

Microsoft Corporation (NASDAQ: MSFT) is trading around record territory again on Friday, November 28, 2025, with the stock hovering near $485.50 per share and supporting an estimated market capitalization of about $3.6 trillion.

Despite a choppy November for technology shares overall, Microsoft remains one of the market’s core AI and cloud bellwethers, priced at a premium valuation as investors continue to pay up for its growth in Azure, Copilot, and AI infrastructure.


Microsoft share price and key stats on November 28, 2025

Based on the latest available data:

  • Last trading price: about $485.50 per share
  • Market capitalization: roughly $3.61 trillion
  • Trailing 12‑month EPS: around $14.06
  • Trailing P/E ratio: approximately 34.5× (P/E = 485.50 ÷ 14.06)
  • 12‑month trading range: roughly $344.79 (low) to $555.45 (high)
  • Dividend yield: about 0.7%, based on a quarterly dividend of $0.91 per share after a recent increase from $0.83

Recent filings and market data also show institutional investors controlling just over 71% of the float, with major holders like Vanguard, Northern Trust and Goldman Sachs steadily adding to positions.

For context, Microsoft’s P/E of ~34.5 is:

  • Clearly higher than the forward P/E of the S&P 500, which sits near 23×
  • Roughly in line with the Nasdaq‑100’s mid‑30s P/E, which underscores its status as a premium mega‑cap tech name

That valuation profile is central to how investors are reading MSFT today: the market is paying a “quality + AI leadership” premium, while keeping a close eye on how quickly those AI investments translate into durable profits.


AI and cloud are still the engine of Microsoft’s growth

Microsoft’s most recent results continue to show double‑digit top‑line growth driven primarily by its cloud and AI offerings.

In its fiscal 2026 first quarter (ended September 30, 2025), Microsoft reported:

  • Revenue: $77.7 billion, up 18% year over year
  • Operating income: $38.0 billion, up 24%
  • GAAP EPS: $3.72, up 13%
  • Non‑GAAP EPS: $4.13, up 23%

The real story is the cloud and AI layer:

  • Microsoft Cloud revenue reached $49.1 billion, up 26% year over year.
  • Intelligent Cloud revenue grew 28%, with Azure and other cloud services up about 40%.

Those numbers build on a record fiscal 2025, where revenue rose 15% to $281.7 billion, operating income climbed 17% to $128.5 billion, and Azure surpassed $75 billion in annual revenue, growing roughly 34%.

This momentum is reinforced by industry data: in Q3 2025, Microsoft held about 20% of the global cloud infrastructure services market, second only to Amazon Web Services at ~29%, with Google Cloud at around 13%.

In short, today’s $3.6 trillion valuation is anchored in a business that’s:

  • Growing revenue at a mid‑teens pace at corporate level
  • Growing Azure and cloud in the high‑20s to 40% range
  • Leaning heavily into AI workloads, from copilots to industry‑specific solutions

Fresh headlines shaping Microsoft’s stock narrative today

A few recent developments are especially relevant for investors watching MSFT on November 28:

1. Deeper push into medical AI

Microsoft is moving aggressively into healthcare AI, integrating Dragon Medical’s “Dragon Copilot” into PowerScribe One, its widely used radiology reporting platform. The idea is to help radiologists automate routine reporting tasks and surface key clinical details directly inside tools they already use, rather than forcing them into new workflows. Insider Monkey

The same report highlights that Truist analyst Terry Tillman recently reiterated a “Buy” rating with a $675 price target, citing Microsoft’s accelerating AI strategy (including copilots and autonomous agents) as a central driver of long‑term growth expectations. Insider Monkey+1

2. Easing pressure on EU cloud antitrust front – sort of

Another notable piece of news is that Google has withdrawn its EU antitrust complaint against Microsoft’s cloud business, which had alleged anti‑competitive tactics around Azure licensing. The withdrawal came shortly after EU regulators launched a broader probe into cloud sector practices, potentially designating both Azure and AWS as “gatekeepers” under the Digital Markets Act. CoinCentral

For Microsoft shareholders, this is a mixed signal:

  • Positive: one high‑profile, company‑on‑company complaint goes away.
  • Cautionary: the regulatory spotlight is now squarely on the entire cloud sector, and any gatekeeper designation could bring new obligations or constraints.

3. Governance and CEO pay in focus ahead of December AGM

On the governance side, analysis from Simply Wall St notes that Microsoft will hold its Annual General Meeting on December 5, with CEO Satya Nadella’s compensation likely to be discussed. His total pay of about $96 million is significantly above the industry median, though the company has delivered strong results – three‑year EPS growth around 15% per year and a total shareholder return near 95% over that period.

Shareholders appear broadly satisfied with performance, but many will be watching how the board balances executive pay with long‑term returns and ongoing AI investment needs.

4. Strong institutional demand despite volatility

New SEC filings show smaller but notable investors such as Yukon Wealth Management Inc. and Solstein Capital LLC boosting their Microsoft stakes, making MSFT among their top positions. Their moves add to a long list of large institutional holders, with about 71% of Microsoft shares held by institutions and hedge funds.

This high institutional ownership can amplify both support on pullbacks and volatility when big funds rebalance, which is important to keep in mind given the stock’s premium valuation.


Valuation check: how “expensive” is Microsoft today?

At today’s levels, Microsoft is trading at:

  • ~34.5× trailing earnings
  • A PEG ratio (P/E divided by expected earnings growth) around 2.3–2.4

Compared with major indices:

  • The S&P 500 forward P/E is close to 23×, a level commentators have already called elevated versus long‑term history.
  • The Nasdaq‑100 P/E sits around 34×, making Microsoft’s earnings multiple broadly in line with the wider mega‑cap tech cohort.

What this implies:

  • Microsoft is not cheap on traditional metrics, especially versus the broader market.
  • However, its valuation is consistent with – and slightly more defensible than – other AI and cloud leaders, thanks to its diversified revenue base, recurring software revenue and massive free cash flow.

Investors are effectively paying a premium for:

  1. Durable double‑digit growth in cloud and AI.
  2. Best‑in‑class margins and returns on equity north of 30%.
  3. A balance sheet capable of absorbing huge AI capex while still raising dividends and buying back stock.

The key debate for 2026 and beyond is whether AI monetization and cloud growth can stay strong enough to justify that premium if macro conditions or tech sentiment weaken.


Macro backdrop: AI excitement vs. valuation fatigue

Zooming out, U.S. equities are having a strong 2025, with the S&P 500 up roughly 16% year to date. AI‑linked names have played a big role in that rally, but there’s growing concern about how fast profits will catch up to AI infrastructure spending.

Within tech:

  • The information‑technology sector is up more than 20% so far this year, but it actually fell about 4–5% in November, as only a minority of large tech stocks posted monthly gains.
  • Investors are becoming more selective, rewarding companies that show concrete AI revenue and margin uplift and punishing those perceived as over‑spending without clear payback.

Microsoft sits squarely in the middle of that conversation. It’s spending heavily on AI data centers and OpenAI‑related infrastructure, which has slightly pressured cloud margins, but it is also clearly demonstrating revenue growth and pricing power in its AI‑enhanced products.


Key catalysts and risks to watch from here

For anyone following Microsoft stock into year‑end and early 2026, a few themes stand out:

1. Next earnings and AI monetization updates

Investors will be looking for:

  • Continued 30–40% growth in Azure and other cloud services
  • Evidence that Copilot and other AI features are driving higher seat counts, ARPU (revenue per user), or tier upgrades
  • Commentary on how quickly AI infrastructure capex will stabilize versus the revenue ramp

Any sign that AI demand is slowing or that costs are rising faster than expected could pressure the stock’s multiple.

2. Regulatory outcomes in Europe and beyond

While Google’s withdrawal of its complaint removes one direct source of friction, the EU’s broader cloud investigation and the possibility of a “gatekeeper” label for Azure remain real overhangs. Outcomes here could affect:

  • How Microsoft structures cloud licensing and bundling
  • The profitability of certain cloud services in Europe
  • The competitive dynamics versus AWS and Google Cloud

3. Capital allocation: dividends, buybacks, and AI capex

Microsoft continues to raise its dividend and execute substantial buybacks – it returned $9.4 billion to shareholders in Q4 FY25 and $10.7 billion in Q1 FY26 via dividends and repurchases.

At the same time, it’s committing tens of billions to:

  • AI‑ready data centers
  • Specialized chips and partnerships
  • Ongoing investments in OpenAI and related ecosystems

The balance between shareholder returns and AI reinvestment will be increasingly scrutinized, especially if economic data softens or rate‑cut expectations change.

4. Governance and long‑term incentives

The upcoming AGM on December 5 will shine a spotlight on executive pay, board oversight and long‑term incentive structures. For long‑horizon investors, how Microsoft links pay to AI adoption, cloud share, and sustainability goals matters almost as much as the next quarter’s EPS beat.


Bottom line on Microsoft stock today

On November 28, 2025, Microsoft stock is:

  • Trading near $485.50, within striking distance of all‑time highs but still about 12–13% below its 12‑month peak around $555.
  • Valued at roughly 34.5× earnings and $3.6 trillion in market cap, in line with the richest names in the Nasdaq‑100.
  • Backed by rapid growth in cloud and AI, with Azure and Microsoft Cloud continuing to post high‑20s to 40% growth off an already huge base.
  • Facing regulatory, valuation and capex risks, but also enjoying strong institutional support and overwhelmingly positive Wall Street ratings, with a consensus price target around $630–$635, well above today’s level.

For readers following MSFT on Google News or Discover, the key takeaway is that Microsoft remains a central way to express a view on the AI and cloud computing boom. Whether that makes the stock attractive at today’s price depends on your risk tolerance, time horizon, and views on how quickly AI spending will convert into durable, high‑margin revenue.

Disclosure: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Always do your own research or consult a licensed financial adviser before making investment decisions.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Denny’s Closes Santa Rosa and Barrie Locations as 150 Restaurants Face Axe After $620 Million Sale
Previous Story

Denny’s Closes Santa Rosa and Barrie Locations as 150 Restaurants Face Axe After $620 Million Sale

Denny’s Closures in Santa Rosa and Canada: What the $620 Million Buyout Really Means for ‘America’s Diner’
Next Story

Denny’s Closures in Santa Rosa and Canada: What the $620 Million Buyout Really Means for ‘America’s Diner’

Go toTop